Skip to content
Screener

Enliven Therapeutics ELVN Retained Earnings

Retained Earnings at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$20.32B+25.8%
Pfizer logo
PfizerPFE
$117.24B-2.0%
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
-$4.36B-24.4%
Iovance Biotherapeutics, Inc. logo
Iovance Biotherapeutics, Inc.IOVA
-$2.9B-11.1%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$1.55B-18.6%
CTO
Citius Oncology, Inc.CTOR
-$96.18M-79.2%

Other financials

Income statement

See full
Operating income-$27.8M+12.2%
Net income-$23.6M+17.2%
EPS (diluted)-$0.38+33.3%

Balance sheet

See full
Cash & equivalents$132.2M+30.0%
Total debt$302.0K-56.9%
Total equity$453.4M+57.3%
Total assets$464.9M+53.6%

Cash flow

See full
Operating cash flow-$19.3M+20.0%
CapEx--100%
Free cash flow-$19.3M+20.1%

Valuation

See full
Market cap$4.42B+297%
Enterprise value$4.28B+332%

Returns & leverage

See full
Return on equity-26.6%-3.5pp
Debt / equity0.0×
Current ratio40.3×+19.3×

Where this comes from

Reported directly by Enliven Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.

The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.

Filed
May 7, 2026, 4:17 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-211982
Line itemAs of / March 31, 2026As of / December 31, 2025
Stockholders' equity:
Preferred stock, par value $0.001; authorized shares - 10,000,000;issued and outstanding shares - none
Common stock, par value $0.001; authorized shares - 100,000,000;issued and outstanding shares - 60,889,655 and 59,440,045 atMarch 31, 2026 and December 31, 2025, respectively6159
Additional paid-in capital824,479806,373
Accumulated other comprehensive (loss) income(382)334
Accumulated deficit(370,793)(347,166)
Total stockholders’ equity453,365459,600
Total liabilities and stockholders' equity$464,852$476,168

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Enliven Therapeutics's retained earnings?
Enliven Therapeutics (ELVN) reported retained earnings of -$370.79M in Q1 2026.
How has Enliven Therapeutics's retained earnings changed year-over-year?
Enliven Therapeutics's retained earnings decreased by 36.3% year-over-year, from -$272.02M to -$370.79M.
What is the long-term trend for Enliven Therapeutics's retained earnings?
Over 5 years (2020 to 2025), Enliven Therapeutics's retained earnings has grown at a 29.3% compound annual growth rate (CAGR), from -$96.11M to -$347.17M.
What does retained earnings mean?
Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.

Ask your AI about Enliven Therapeutics's retained earnings.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude